Harel Insurance Investments & Financial Services Ltd. Its position is in shares of CVS Health Co. (NYSE: CVS – Get Rating) increased by 90.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owns 300 shares of the pharmacy operator after selling 2,700 shares during the period. The holdings of Harel Insurance Investments & Financial Services Ltd. in CVS Health $28,000 as of its most recent filing with the SEC.
→ A banking nightmare (from Vice ratings)
Other institutional investors have also added or reduced their stakes in the company. CWA Asset Management Group LLC strengthened its position in CVS Health by 5.0% in the fourth quarter. CWA Asset Management Group LLC now owns 12,665 shares of the pharmacy operator valued at $1,180,000 after purchasing an additional 605 shares during the last quarter. Gofen & Glossberg LLC IL increased its position in shares of CVS Health by 10.1% during the fourth quarter. Gofen & Glossberg LLC IL now owns 34,429 shares of the pharmacy operator valued at $3,208,000 after purchasing an additional 3,172 shares last quarter. Diversified Trust increased its stake in CVS Health by 1.0% in the third quarter. Diversified Trust Co now owns 14,899 shares of the pharmacy operator valued at $1,421,000 after acquiring an additional 145 shares during the most recent quarter. Carnegie Capital Asset Management LLC grew its position in CVS Health by 28.9% in the third quarter. Carnegie Capital Asset Management LLC now owns 55,867 shares of the pharmacy operator valued at $5,328,000 after acquiring an additional 12,527 shares last quarter. Finally, Bond & Devick Financial Network Inc. Its position in CVS Health increased 1.9% during the third quarter. Bond & Devick Financial Network Inc. Now 10,820 shares of the pharmacy operator valued at $1,032,000 after purchasing an additional 200 shares during the period. Hedge funds and other institutional investors own 77.29% of the company’s shares.
CVS Health Trading fell 0.3%
NYSE CVS opened at $77.54 on Friday. The company’s 50-day simple moving average is $81.37 and its 200-day simple moving average is $90.29. CVS Health Co has a one-year low of $72.11 and a one-year high of $107.73. The company has a market capitalization of $99.57 billion, a price-to-earnings ratio of 24.85, a price-to-earnings growth ratio of 1.20 and a beta of 0.61. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.67 and a trading ratio of 0.94.
CVS Health (NYSE: CVS – Get Rating) last published its earnings results on Wednesday, February 8th. The pharmacy operator reported earnings of $1.99 per share for the quarter, topping analyst consensus estimates of $1.92 by $0.07. The company’s revenue was $83.85 billion for the quarter, compared to analyst estimates of $76.37 billion. CVS Health had a return on equity of 15.75% and a net margin of 1.29%. CVS Health revenue increased 9.5% year-over-year. During the same quarter in the previous year, the company had earnings of $1.98 per share. Equity analysts expect CVS Health Co to report 8.83 earnings per share for the current fiscal year.
CVS Health announces the dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Friday, April 21st will be issued a dividend of $0.605. This represents a dividend of $2.42 yoy and a dividend yield of 3.12%. Due date is Thursday, April 20th. CVS Health’s dividend yield is currently 77.56%.
Wall Street analyst weighs in
Many equities analysts have recently weighed in on the CVS stock. Raymond James cut price target on CVS Health from $115.00 to $110.00 and put a “outperform” rating on the stock in a research report on Thursday, February 9th. Morgan Stanley increased its price target for shares of CVS Health from $119.00 to $120.00 and assigned the company an “overweight” rating in a research note on Friday, January 13th. Royal Bank of Canada reiterated “outperform” rating and set a price target of $115.00 on shares of CVS Health in a report on Thursday, February 9th. StockNews.com assumed coverage of shares of CVS Health in a research note on Thursday, March 16th. They issued a “Buy” rating to the company. Finally, Jefferies Financial Group raised its price target on CVS Health from $130.00 to $143.00 and gave the stock a “buy” rating in a report on Thursday, February 9th. Two equities research analysts have rated the stock with a hold rating, and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and an average price target of $118.24.
CVS Health Company Profile
CVS Health Corp. It is a health solutions company engaged in providing healthcare services. It operates through the following divisions: Pharmacy Services, Retail or Long Term Care Services, Health Care Benefits, Corporate and Others. The Pharmacy Services division focuses on pharmacy benefits management solutions.
This instant news alert was created by MarketBeat’s narrative science and financial data technology to provide readers with the fastest, most accurate reporting possible. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider CVS Health, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on…and CVS Health wasn’t on the list.
While CVS Health currently has a “moderate buy” rating among analysts, the top-rated analysts think these five stocks are better buys.
View the five stocks here